Second‐line immunotherapy in new onset refractory status epilepticus
Most Cited Paper
in Epilepsy research and treatment
18 Months Post-Publication
Class of 2026
“Second‐line immunotherapy in new onset refractory status epilepticus”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
New-onset refractory status epilepticus (NORSE) · NORSE · Febrile infection-related epilepsy syndrome (FIRES) · FIRES · second-line immunotherapy · anakinra · tocilizumab · intrathecal dexamethasone · cytokine levels · Cerebrospinal fluid cytokines · serum cytokines · seizure control · immune dysregulation · post-NORSE epilepsy · Drug-resistant epilepsy · status epilepticus · immunomodulation · acute phase treatment · long-term functional outcomes
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Epilepsy research and treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/epilepsy-research-and-treatment/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459